You are here: Industry Insights > GC pharma

News List

GC Pharma partners with Speragen to develop first in class drug for a rare disease firstwordpharma
July 21, 2021
South Korean biopharmaceutical firm GC Pharma has partnered with US-based Speragen to develop an enzyme replacement therapy for succinic semialdehyde dehydrogenase deficiency, reported The Korea Herald.
Grifols to acquire GC Pharma’s plasma fractionation facility for $460m pharmaceutical-technology
July 22, 2020
Plasma-derived medicines company Grifols has executed purchase arrangements with South Korean-based GC Pharma to acquire a plasma fractionation facility in Montreal, Canada for $460m.
Grifols to Acquire GC Pharma’s Plasma Facilities for $460M contractpharma
July 21, 2020
Gains Montreal-based plasma fractionation facility, two purification facilities, and 11 U.S.-based plasma collection centers.
GC Pharma Reports Q2 2019 Results prnasia
August 06, 2019
GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months ended June 30, 2019.
Clinigen K.K., GC Pharma sign pact to market Hunterase ICV biospectrumasia
April 08, 2019
Clinigen K.K. and GC Pharma have recently announced an exclusive licensing agreement in Japan to commercialize Hunterase (Idursulfase-beta) ICV
Korea's GC Pharma establishes vaccine development firm in Seattle biospectrumasia
May 28, 2018
The new company aims to bring together GC Pharma's commercial scale vaccine development expertise and deep understanding of protein science with IDRI and MIBR's world class scientific expertise in vaccine, adjuvant and formulation development
GC Pharma, IDRI, MIBR Launch Curevo contractpharma
May 22, 2018
GC Pharma, a South Korean biopharmaceutical company, announced the establishment of Curevo Inc.
GC pharma announces approval for Lantus biosimilar in Korea biospectrumasia
March 15, 2018
The company plans to launch Glarzia Prefilled Pen, a Lantus biosimilar developed by Indian drug maker Biocon, in the third quarter this year